Related content

Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen

By Scarpi E.  

Breast Cancer Research and Treatment, Vol. 68, Iss. 2, 2001-07 ,pp. : 101-110

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel: In the Treatment of Operable Breast Cancer

By Susan J. Keam   Lesley J. Scott  

American Journal of Cancer, Vol. 3, Iss. 5, 2004-01 ,pp. : 325-332

Adis International

Access to resources Recommend Favorite

Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR

By Berois N.   Varangot M.   Aizen B.   Estrugo R.   Zarantonelli L.   Fernandez P.   Krygier G.   Simonet F.   Barrios E.   Muse I.   Osinaga E.  

European Journal of Cancer, Vol. 36, Iss. 6, 2000-04 ,pp. : 717-723

Elsevier

Access to resources Recommend Favorite

High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer

By Met Özcan   Balslev Eva   Flyger Henrik   Svane Inge  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 395-406

Springer Publishing Company

Access to resources Recommend Favorite

Vaccination with p53-peptide–pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study

By Svane Inge   Pedersen Anders   Johnsen Hans   Nielsen Dorte   Kamby Claus   Gaarsdal Eva   Nikolajsen Kirsten   Buus Søren   Claesson Mogens  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 7, 2004-07 ,pp. : 633-641

Springer Publishing Company

Access to resources Recommend Favorite